Literature DB >> 14967452

The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data.

Arnab Chakravarti1, Adam Dicker, Minesh Mehta.   

Abstract

PURPOSE: The epidermal growth factor receptor (EGFR) pathway is frequently upregulated in high-grade gliomas via gene amplification and by specific mutations that render EGFR constitutively active (EGFRvIII). METHODS AND MATERIALS: This review highlights EGFR's role in mediating radiation resistance in gliomas: underlying molecular mechanisms, with discussion of relevant preclinical and clinical correlative data.
RESULTS: Preclinical and emerging clinical data suggest that EGFR signaling plays a potentially important role in mediating radiation resistance in human gliomas.
CONCLUSIONS: Targeting EGFR alone, or in combination with its downstream mediators, represents a promising new approach for the management of glioma patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14967452     DOI: 10.1016/j.ijrobp.2003.09.092

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  46 in total

1.  Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres.

Authors:  Alicia M Mihaliak; Candace A Gilbert; Li Li; Marie-Claire Daou; Richard P Moser; Andrew Reeves; Brent H Cochran; Alonzo H Ross
Journal:  Cancer Lett       Date:  2010-10-28       Impact factor: 8.679

2.  3,3'-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutants.

Authors:  Massod Rahimi; Kai-Ling Huang; Careen K Tang
Journal:  Cancer Lett       Date:  2010-03-17       Impact factor: 8.679

3.  Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter.

Authors:  Khatri Latha; Ming Li; Vaibhav Chumbalkar; Anupama Gururaj; YeoHyeon Hwang; Sumana Dakeng; Raymond Sawaya; Kenneth Aldape; Webster K Cavenee; Oliver Bogler; Frank B Furnari
Journal:  Int J Cancer       Date:  2012-07-09       Impact factor: 7.396

4.  EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma.

Authors:  Costas G Hadjipanayis; Revaz Machaidze; Milota Kaluzova; Liya Wang; Albert J Schuette; Hongwei Chen; Xinying Wu; Hui Mao
Journal:  Cancer Res       Date:  2010-07-20       Impact factor: 12.701

5.  Targeting of EGFR and HER2 with therapeutic antibodies and siRNA: a comparative study in glioblastoma cells.

Authors:  Henri Wichmann; Antje Güttler; Matthias Bache; Helge Taubert; Swetlana Rot; Jacqueline Kessler; Alexander W Eckert; Matthias Kappler; Dirk Vordermark
Journal:  Strahlenther Onkol       Date:  2014-08-27       Impact factor: 3.621

Review 6.  Impact of molecular profiling on clinical trial design for glioblastoma.

Authors:  Arnab Chakravarti; Erin Tyndall; Kamalakannan Palanichamy; Minesh Mehta; Kenneth Aldape; Jay Loeffler
Journal:  Curr Oncol Rep       Date:  2007-01       Impact factor: 5.075

Review 7.  Designing clinical trials for brain tumors: the next generation.

Authors:  Mark R Gilbert
Journal:  Curr Oncol Rep       Date:  2007-01       Impact factor: 5.075

Review 8.  Pediatric Craniopharyngiomas: A Primer for the Skull Base Surgeon.

Authors:  Christopher Salvatore Graffeo; Avital Perry; Michael J Link; David J Daniels
Journal:  J Neurol Surg B Skull Base       Date:  2018-01-19

9.  Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2.

Authors:  Min Zheng; Susan E Morgan-Lappe; Jie Yang; Katrina M Bockbrader; Deepika Pamarthy; Dafydd Thomas; Stephen W Fesik; Yi Sun
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

10.  Temozolomide-mediated radiosensitization of human glioma cells in a zebrafish embryonic system.

Authors:  Geoffrey A Geiger; Weili Fu; Gary D Kao
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.